Intraprocedural Protocol for Cerebral ICAD Stenting
For intracranial atherosclerotic disease stenting, administer an initial intravenous heparin bolus of 5,000-10,000 units (or 70 U/kg body weight) at procedure start, maintain activated clotting time between 250-300 seconds throughout the procedure, and target residual stenosis ≤50% as technical success. 1
Pre-Procedure Antiplatelet Loading
- Dual antiplatelet therapy must be initiated days before the procedure to prevent periprocedural platelet emboli 1
- Aspirin: 81-325 mg daily (dosing varies by operator)
- Clopidogrel: 75-300 mg daily before procedure
- Critical caveat: Patients with recent ischemic strokes are prone to hemorrhagic complications on dual antiplatelet therapy, with MATCH trial showing 1.3% absolute increase in life-threatening bleeding 1
Intraprocedural Anticoagulation Protocol
Heparin Administration
- Initial bolus: 5,000-10,000 units IV or weight-based 70 U/kg at procedure start 1
- For patients on glycoprotein IIb/IIIa inhibitors: reduce to 50 U/kg 1
- Target ACT range: 250-300 seconds (acceptable ranges reported from 150-350 seconds, but 250-300 represents consensus) 1
- Post-procedure: Either stop immediately or continue up to 24 hours depending on individual patient factors 1
- Do not reverse heparin at procedure end 1
Blood Pressure Management
This is critical to prevent hyperperfusion syndrome, which occurs in up to 9% of cases and can cause devastating intracranial hemorrhage 1
- Maintain pharmacologically-induced hypotension post-revascularization - normal blood pressure represents effective "hypertension" for the newly revascularized brain 1
- Pre-procedure: Some patients require withholding antihypertensives or even IV vasopressors to maintain perfusion until revascularization 1
- Post-procedure: Aggressive blood pressure control is essential as the brain loses cerebrovascular autoregulation
Technical Procedure Details
Device Selection
- WingSpan Stent System with Gateway PTA Balloon is FDA-approved specifically for intracranial applications (2005) 1
- Major advantage: slow stent expansion over weeks, minimizing vessel dissection/rupture risk 1
- Avoid drug-eluting stents - they show increased death/MI rates compared to bare-metal stents and require prolonged dual antiplatelet therapy (12-24 months vs 4 weeks), increasing hemorrhagic risk 1
Technical Success Definition
- Target: ≤50% residual stenosis 1
- WingSpan Registry data: average stenosis 43.5±18.1% after angioplasty alone, 27.2±16.7% after stent deployment 1
Management of Acute Intraprocedural Occlusion
Acute occlusion occurs from mechanical dissection, thrombus formation, or severe vasospasm 1
Treatment options:
- Intra-arterial thrombolytic infusion
- Glycoprotein IIb/IIIa antagonists 1
- Rapid revascularization often prevents clinical consequences 1
Post-Procedure Antiplatelet Regimen
Standard protocol from WingSpan Registry 1:
- Aspirin 325 mg daily + Clopidogrel 75 mg daily for minimum 4 weeks
- After 4 weeks: continue aspirin 325 mg daily alone
- For bare-metal stents, this 4-week dual therapy is adequate
Alternative from SSYLVIA trial 1:
- Aspirin ≥100 mg daily for minimum 1 year
- Clopidogrel 75 mg daily for at least 4 weeks
Special Considerations
Renal Protection (for patients with chronic renal failure)
- IV hydration
- N-acetylcysteine or bicarbonate treatment before intervention 1
Neuroprotection
- Nimodipine use (oral 60 mg or IV 0.6-2.0 mg/hour) remains unproven 1
Operator Requirements
Only appropriately trained neurovascular interventionalists should perform these procedures - formal training in both cognitive and technical neuroscience aspects is essential per joint society statement 1
Common Pitfalls
- Inadequate antiplatelet loading - must be done days in advance, not acutely
- Failure to aggressively control blood pressure post-procedure - hyperperfusion syndrome is preventable but devastating
- Using drug-eluting stents - increased thrombosis risk and bleeding from prolonged dual antiplatelet therapy outweighs benefits
- Reversing heparin at procedure end - should not be done
- Inadequate ACT monitoring - must maintain therapeutic range throughout